See also this year's filing and all EDGAR filings for this company.
PDF Report 0000707511_2021_REGENERX_BIOPHARMACEUTICALS_INC.pdf
Logs
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'PROVECTUS BIOPHARMACEUTICALS INC.', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.024349360544169574, 'aggregate_val': 551788, 'exp_sum': 565559, 'exp_to_value': {'AssetsCurrent': 477807, 'IntangibleAssetsNetIncludingGoodwill': 0, 'PropertyPlantAndEquipmentNet': 0, 'remainder_Assets': 87752}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0000707511')"} |
Graph
Absolute values for 0000707511, REGENERX BIOPHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 477,807 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 0 |
| 3 | remainder_Assets | 73,981 |
| 4 | LiabilitiesCurrent | 399,584 |
| 5 | LiabilitiesNoncurrent | 2,052,373 |
| 6 | remainder_Liabilities | 923,775 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 1,366,383 |
| 9 | ResearchAndDevelopmentExpense | 4,921 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 76,761 |
| 12 | remainder_NetIncome | -228,825 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 551,788 |
| 1 | Liabilities | 3,375,732 |
| 2 | Expenses | 1,371,304 |
| 3 | Revenues | 76,761 |
| 4 | StockholdersEquity | -2,823,944 |
| 5 | NetIncome | -1,523,368 |
| 6 | ComprehensiveNetIncome | -1,523,368 |
| 7 | BaseVar | 2,802,205 |
| 8 | EconomicCapitalRatio | -3.25 |
Edgar->Model Mapping
Feature Distribution
Change over Time
